CNS Pharmaceuticals Investor Relations Material

CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company engaged in the development of anti-cancer drug candidates. Its primary focus is on treatments for primary and metastatic cancers of the brain and central nervous system malignancies. The company's flagship drug candidate, Berubicin, is a novel anthracycline, notable for being the first of its kind to cross the blood-brain barrier. This drug is currently in development for the treatment of glioblastoma multiforme (GBM), a particularly aggressive and currently incurable form of brain cancer. In addition to Berubicin, CNS Pharmaceuticals is advancing WP1244, a drug technology that leverages anthracycline and distamycin-based scaffolds to create potent small molecule agents. The company is headquartered in Houston, Texas, and its shares are listed on the Nasdaq.